Theravance Biopharma Inc

Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions

Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025

Theravance Biopharma to Participate in Upcoming Investor Conferences

Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update